Clinical Obstetrics & Gynecology,
Journal Year:
2024,
Volume and Issue:
67(3), P. 620 - 632
Published: July 4, 2024
Malaria
still
presents
a
grave
threat
to
the
health
of
pregnancies
worldwide
with
prevention
currently
stalling
as
traditional
control
and
strategies
are
limited
by
both
insecticide
drug
resistance.
Furthermore,
climate
change
is
bringing
malaria
locations
where
it
was
once
eradicated
intensifying
in
other
areas.
Even
not
common,
obstetricians
will
need
understand
pathogenesis
disease,
how
transmitted,
methods
for
treatment
pregnancy,
promising
emerging
such
vaccines.
A
renewed
global
response
needed
this
age-old
disease
which
pregnancy
poses
specific
susceptibility.
Biosensors,
Journal Year:
2025,
Volume and Issue:
15(2), P. 106 - 106
Published: Feb. 12, 2025
Malaria
is
a
tropical
disease
caused
by
the
Plasmodium
parasite,
which
was
responsible
for
249
million
cases
worldwide
in
2022.
currently
diagnosed
using
RDTs,
PCR-based
methods,
or
blood
smear
microscopy.
Ideal
biomarkers
have
been
identified
malaria,
with
potential
improving
treatment,
diagnosis,
and
overall
clinical
outcomes.
This
review
discusses
types
of
existing
opportunities
new
to
be
used
as
diagnostic
components
detecting
Plasmodium,
including
terms
sensitivity,
detection
limit,
specificity,
species
that
can
detected.
Following
comparison,
five
main
ideal
malaria
were
identified,
namely
HRP2,
pLDH,
hemozoin,
aldolase,
pGDH.
These
distinguished
themselves
markedly
from
others
specificity
detection,
sensitivity
analysis,
use
non-invasive
samples.
Several
other
biomarkers,
such
CRP,
Ang-1,
Ang-2,
PCT,
show
their
ability
differentiate
severity,
levels
these
determined
body
comparison
parasitemia.
Of
hemozoin
aldolase
still
developed
regarding
samples
different
species.
Further
research
on
PCT
needed
evaluate
potential.
International Journal of Applied Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
unknown, P. 48 - 58
Published: Jan. 7, 2025
Colonization
of
the
erythrocytic
stages
Plasmodium
falciparum
has
become
a
challenging
aspect
in
every
drug
delivery
system
because
it
is
responsible
for
each
clinical
manifestation
and
life-threatening
complication
malaria.
With
emergence
resistance
malarial
parasites
recent
past,
developing
vaccine
against
malaria
still
long-drawn-out
affair.
However,
reports
recombinant
protein-based
from
Glaxo
Smith
Kline
have
initiated
new
ray
hope.
In
such
scenario,
onus
reliable
disease
remains
mainstay
fighting
This
review
delves
into
various
attempts
carried
out
by
researchers
past
to
develop
parasite
throws
light
on
very
outcome
that
provides
targeted
infected
erythrocyte
using
nanotechnology-based
approach.
Considering
eventful
journey
beginning,
was
discovery
chloroquine
created
an
epoch
treatment
Due
its
low
cost
high
efficacy,
became
most
widely
used
antimalarial.
Until
1960s,
Chloroquine
(CQ)
best
solution
but
scenario
changed
1970s
due
widespread
falciparum,
vivax
parts
world.
This,
turn,
led
development
novel
systems
liposomes
Solid
Lipid
Nanoparticles
(SLN)
more
effective
site-specific
erythrocytes.
Such
later
use
approach
which
included
nanospheres
nanoparticulate
carriers.
Malaria Journal,
Journal Year:
2025,
Volume and Issue:
24(1)
Published: Jan. 17, 2025
Malaria
remains
a
significant
public
health
challenge,
particularly
in
low-
and
middle-income
countries,
despite
ongoing
efforts
to
eradicate
the
disease.
Recent
advancements,
including
rollout
of
malaria
vaccines,
such
as
RTS,S/AS01
R21/Matrix-M™,
offer
new
avenues
for
prevention.
However,
rise
resistance
anti-malarial
medications
necessitates
innovative
strategies.
This
review
explores
potential
integration
CRISPR/Cas9
gene
drive
technology
with
vaccination
enhance
vector
control
reduce
transmission.
By
employing
mechanisms
population
suppression
replacement
malaria-transmitting
Anopheles
mosquitoes,
combined
immunogenic
properties
synergistic
approach
can
be
established.
paper
discussed
need
integrated
strategies
address
biological
complexities
socio-economic
factors
influencing
its
prevalence.
Challenges
regulatory
hurdles,
community
acceptance,
ecological
impacts,
sustainable
funding
are
examined,
alongside
implementation
within
existing
programmes.
could
significantly
contribute
achieving
World
Health
Organization's
targets
reduction
by
2030,
ultimately
enhancing
outcomes
supporting
broader
development.
Indus journal of bioscience research.,
Journal Year:
2025,
Volume and Issue:
3(2)
Published: March 18, 2025
Background:
Pneumonia
is
an
inflammatory
condition
of
the
lungs
caused
by
bacterium
Streptococcus
pneumoniae.
It
a
significant
cause
mortality
and
morbidity,
particularly
among
young
children,
adults
immunocompromised
persons.
Resistance
against
drugs
continuously
evolving
in
nearly
all
pathogens.
The
constant
need
for
alternative
therapeutic
options
demands
necessity
ongoing
search
novel
drugs.
Objective:
current
study
was
thus
designed
to
target
penicillin
binding
protein
pneumoniae
(PBP1a),
involved
critical
cellular
metabolic
processes.
Method:
PBP1a
sequence
obtained
from
UniProt
database
BLAST
performed.
3D
structure
downloaded
RCSB
visualized
using
Discovery
Studio
Visualizer.
150
were
docked
PatchDock
web
server
interactions
explored
GS
Viewer,
LigPlot+
Result:
Out
chosen,
Lamivudine,
Dolutegravir
Loperamide
showed
most
with
PBP1a.
These
included
covalent
bonds,
hydrogen
bonds
hydrophobic
interactions.
Conclusion:
interacted
uniquely
protein.
may
trigger
changes
could
inhibit
growth
kill
parasite.
Further
experimental
needed
fully
understand
potential
these
